Cinacalcet tablets case: Cipla, Amgen settle legal dispute
Mumbai/UNI: Pharma major, Cipla on Monday said company has settled a a legal dispute with Amgen in the United States involving generic cinacalcet hydrochloride tablets , used in treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease.
"The civil action filed by Cipla Ltd and Cipla USA Inc, wholly owned step-down subsidiary of Cipla Ltd (hereinafter together referred to as Cipla), in the US District Court for the District of Delaware in January 2019 has been resolved as between Cipla and Amgen Inc," Cipla said in a filing with BSE.
A formal stipulation of dismissal has been filed with the court and is awaiting signature by the presiding Judge, the filing added.
The resolution enables Cipla and its affiliates to continue importing, marketing and selling its generic cinacalcet hydrochloride tablets 30mg, 60mg and 90mg in the US.
Cipla's cinacalcet hydrochloride tablets, in the strengths of 30mg, 60mg and 90mg, are generic versions of Sensipar, a branded drug marketed by Amgen Inc.
Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
